Most frequent pathologies behind corticobasal syndrome

Too bad this full article is in Japanese as it might be a very good review of corticobasal syndrome.

Most impressive to me about the abstract is the long list of disorders that can look like corticobasal syndrome — CBD, AD, PSP, FTLD with TDP-43, Pick’s disease, Lewy body disease, CJD, etc.

Clearly, the only way to be sure of the diagnosis is for the brain to be examined upon death.  If you haven’t made arrangements for that but would like to, please let me know, as we can help with this.  Half of our local group members are involved with brain donation!

Robin

———————-

Brain & Nerve. 2012 Apr;64(4):462-73.

[Corticobasal syndrome: recent advances and future directions].
[Article in Japanese]

Aiba I.
Department of Neurology, National Hospital Organization Higashinagoya National Hospital.

Abstract
Corticobasal degeneration (CBD) is a progressive neurodegenerative disorder described by Rebeiz et al. It is characterized by progressive, asymmetric, cortical (eg, apraxia, alien limb phenomena, cortical sensory loss, and myoclonus), and extrapyramidal (eg, rigidity, bradykinesia, dystonia, and tremor) dysfunction.

However, CBD has many clinical phenotypes, and the features used for predicting CBD have low sensitivity.

Therefore, the term corticobasal syndrome (CBS) has been used to characterize such clinical features, whereas the term CBD is used to refer to the pathological disorder.

The most frequent causes of CBS are CBD, followed by Alzheimer’s disease, progressive supranuclear palsy, frontotemporal lobar degeneration with TDP-43 pathology (sporadic and familial), Pick’s disease, Lewy body disease, frontotemporal lobar degeneration with fused in sarcoma-positive inclusions, Creutzfeldt-Jakob disease, and mutations in the microtubule-associated protein tau (MAPT) and progranulin (GRN) genes.

The topography of neurodegeneration dictates the clinical syndrome not according to the underlying pathology.

Researchers have attempted to develop fluid biomarkers or imaging analysis for diagnosing CBS. The aim of this review was to highlight recent advances in CBS diagnosis and discuss future directions.

PubMed ID#:  22481519  (see pubmed.gov for this English-language abstract only)

“You’re Looking at Me Like I Live Here and I Don’t” – New film

The New York Times has a blog called “New Old Age.”  In a recent blog post, a new film
titled “You’re Looking at Me Like I Live Here and I Don’t” is described.

The film, shot in April 2009, stars Mrs. Lee Gorewitz, who lives in a dementia unit
at a care facility in Danville, CA.  The film is basically a picture of dementia from
the inside out.  It will air on PBS stations tonight (March 29) in San Francisco.

The blog post notes:

“Mostly, the camera follows her wanderings through the unit, her
interactions with other residents and staff, her sudden swings from
conviviality to despair to anger. We hear the background noise and
conversation, if you can call it that, of residents and aides. Family
members are never in the frame. We are there only to the extent Mrs.
Gorewitz is. What she cannot tell us, we don’t know. … The title of the
film is simply something Mrs. Gorewitz said one day, sitting at the
edge of her bed, not far from tears and playing with a bunch of small
stuffed animals.”

Here’s a link to the blog post:

http://newoldage.blogs.nytimes.com/2012/03/28/dementia-from-the-inside

Dementia, From the Inside
New York Times
By Jane Gross, Founding Blogger
March 28, 2012, 8:19 am

Sounds like a very powerful movie….

Robin

Mass Genl researchers look at anesthesia and cognitive dysfunction

This post may be of interest to those who have a loved one with dementia, or those contemplating surgery with general (inhaled) anesthesia.

A Boston Globe newspaper article I circulated back in 2007 was about hospital-induced delirium.  In that article, Massachusetts General Hospital researchers drew attention to the anesthetic isoflurane as part of the cause of delirium.

Last week Massachusetts General Hospital distributed a press release on isoflurane; it causes Alzheimer’s-like changes in mammalian brains.  Researchers mention an anesthetic that may be safer — desflurane.

The full press release is copied below.

Robin

——————————

www.massgeneral.org/about/pressrelease.aspx?id=1443

Massachusetts General Hospital Press Release
Study reveals how anesthetic isoflurane induces Alzheimer’s-like changes in mammalian brains
MGH researchers find desflurane may be safer anesthetic option for patients with Alzheimer’s disease
01/Mar/2012

The association of the inhaled anesthetic isoflurane with Alzheimer’s-disease-like changes in mammalian brains may by caused by the drug’s effects on mitochondria, the structures in which most cellular energy is produced.  In a study that will appear in Annals of Neurology and has received early online release, Massachusetts General Hospital (MGH) researchers report that administration of isoflurane impaired the performance of mice on a standard test of learning and memory – a result not seen when another anesthetic, desflurane, was administered.  They also found evidence that the two drugs have significantly different effects on mitochondrial function.

“These are the first results indicating that isoflurane, but not desflurane, may induce neuronal cell death and impair learning and memory by damaging mitochondria,” says Yiying (Laura) Zhang, MD, a research fellow in the MGH Department of Anesthesia, Critical Care and Pain Medicine and the study’s lead author. “This work needs to be confirmed in human studies, but it’s looking like desflurane may be a better anesthetic to use for patients susceptible to cognitive dysfunction, such as Alzheimer’s patients.”

Previous studies have suggested that undergoing surgery and general anesthesia may increase the risk of Alzheimer’s, and it is well known that a small but significant number of surgical patients experience a transient form of cognitive dysfunction in the postoperative period.  In 2008, members of the same MGH research team showed that isoflurane induced Alzheimer’s-like changes – increasing activation of enzymes involved with cell death and generation of the A-beta plaques characteristic of the disease – in the brains of mice.  The current study was designed to explore the underlying mechanism and behavioral consequences of isoflurane-induced brain cell death and to compare isoflurane’s effects with those of desflurane, another common anesthetic that has not been associated with neuronal damage.

In a series of experiments, the investigators found that the application of isoflurane to cultured cells and mouse neurons increased the permeability of mitochondrial membranes; interfered with the balance of ions on either side of the mitochondrial membrane; reduced levels of ATP, the enzyme produced by mitochondria that powers most cellular processes; and increased levels of the cell-death enzyme caspase.  The results also suggested that the first step toward isoflurane-induced cell death was increased generation of reactive oxygen species – unstable oxygen-containing molecules that can damage cellular components. The performance of mice on a standard behavioral test of learning and memory declined significantly two to seven days after administration of isoflurane, compared with the results of a control group.  None of the cellular or behavioral effects of isoflurane were seen when the administered agent was desflurane.

In another study by members of the same research team – appearing in the February issue of Anesthesia and Analgesia and published online in November – about a quarter of surgical patients receiving isoflurane showed some level of cognitive dysfunction a week after surgery, while patients receiving desflurane or spinal anesthesia had no decline in cognitive performance.  That study, conducted in collaboration with investigators from Beijing Friendship Hospital in China, enrolled only 45 patients – 15 in each treatment group – so its results need to be confirmed in significantly larger groups.

“Approximately 8.5 million Alzheimer’s disease patients worldwide will need anesthesia and surgical care every year,” notes Zhongcong Xie, MD, PhD, corresponding author of both studies and director of the Geriatric Anesthesia Research Unit in the MGH Department of Anesthesia, Critical Care and Pain Medicine.  “Developing guidelines for safer anesthesia care for these patients will require collaboration between specialists in anesthesia, neurology, geriatric medicine and other specialties.  As the first step, we need to identify anesthetics that are less likely to contribute to Alzheimer’s disease neuropathogenesis and cognitive dysfunction.”  Xie is an associate professor of Anesthesia at Harvard Medical School (HMS)

Additional co-authors of the Annals of Neurology study are Zhipeng Xu, MD, PhD, Hui Wang, MD, and Yuanlin Dong, MD, MGH Anesthesia; Rudolph Tanzi, PhD, MGH Neurology; Hai Ning Shi, DVM, PhD, MGH Pediatrics; Deborah Culley, MD, and Greg Crosby, MD, Brigham and Women’s Hospital;  and Edward Marcantonia, MD, MS, Beth Israel Deaconess Medical Center.  The study was supported by grants from the National Institutes of Health, the American Geriatrics Society, the Alzheimer’s Association and the Cure Alzheimer’s Fund.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $750 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

Comparing survival time by dementia type (AD, DLB, FTD, VaD, mixed)

These Australian researchers reviewed the literature on survival time with Alzheimer’s Disease, mixed dementia, vascular dementia, frontotemporal dementia, and dementia with Lew bodies.

After reading this abstract, I wondered if the Australian authors were native English speakers.  Lots of sentences are hard to understand!

Example:  “Relative loss of life expectancy decreases with age at diagnosis across varying gender….”

I think this means:  The older you are, the lower your relative loss of life expectancy is.  And this was truth whether you are male or female.

Here’s another weirdly worded sentence:  “We found that the impact overall of dying from dementia decreases with increasing age…”

For me, the two key takeaways were:
* there aren’t enough studies in dementia with Lewy bodies to have a good idea as to survival time
* survival time “cannot be predicted accurately”

I think that’s enough about this paper for all of us.  The abstract is copied below.

Robin

———————————–

International Psychogeriatrics. 2012 Feb 13:1-12. [Epub ahead of print]

Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia.

Brodaty H, Seeher K, Gibson L.
Dementia Collaborative Research Centre, University of New South Wales, Sydney, NSW, Australia.

ABSTRACT
Background: Life expectancy with dementia directly influences rates of prevalence and service needs and is a common question posed by families and patients. As well as years of survival, it is useful to consider years of life lost after a diagnosis of dementia.

Methods: We systematically reviewed the literature on mortality and survival with dementia which were compared to estimated life expectancies in the general population. Both were then compared by age (under 65 years vs. 65+ years), gender, dementia type, severity, and two epochs (prior to and after introduction of cholinesterase inhibitors in 1997).

Results: Survival after a diagnosis of dementia varies considerably and depends on numerous factors and their complex interaction. Relative loss of life expectancy decreases with age at diagnosis across varying gender, dementia subtypes (except for frontotemporal dementia and dementia with Lewy bodies), and severity stages. Numerous study deficiencies precluded a meta-analysis of survival in dementia.

Conclusion: Estimates of years of life lost through dementia may be helpful for patients and their families. Recommendations for future research methods are proposed.

PubMed ID#:  2232533  (see pubmed.gov for this abstract only)

Grief has to do with failure to accept change

This is a lovely New York Times (nytimes.com) article by a gentleman whose grandmother JoAnn was diagnosed with Alzheimer’s seven years ago.  I think the message applies to our approach in coping with any family member’s diagnosis — not just a diagnosis of dementia.

Here’s a key excerpt:

“But what I learned from my grandmother’s journey through Alzheimer’s was that my grief regarding her condition had largely to do with my failure to accept the change she was undergoing.  Regardless of how I felt about it, JoAnn’s change was the truth. What was gone in her was not missing. And the more fully I understood that, the more present I was able to be during her final years.”

Tying in one tidbit from a webinar I was on earlier today, it sounds as if the gentleman was stuck in the “denial” phase of grief and had to get to the “acceptance” stage before he could adjust his thinking “to be present” with his grandmother.

Here’s a link to the full article:

well.blogs.nytimes.com/2012/02/16/finding-joy-in-alzheimers/

Well Blog
Finding Joy in Alzheimer’s
By Robert Leleux
New York Times
February 16, 2012, 12:01 am

The author of the article, Robert Leleux, is the author of the book “The Living End: A Memoir of Forgetting and Forgiving.”

Happy reading!